Erich Platzer - 15 Dec 2021 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Role
Director
Signature
/s/ Janet Clennett as attorney-in-fact for Erich Platzer
Issuer symbol
APTOF
Transactions as of
15 Dec 2021
Net transactions value
+$316,340
Form type
4
Filing time
17 Dec 2021, 12:45:10 UTC
Next filing
20 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APTO Common Shares Purchase $139,080 +120,000 +89% $1.16 255,000 15 Dec 2021 Direct F1
transaction APTO Common Shares Purchase $23,960 +20,000 +7.8% $1.20 275,000 15 Dec 2021 Direct F2
transaction APTO Common Shares Purchase $35,700 +30,000 +11% $1.19 305,000 15 Dec 2021 Direct
transaction APTO Common Shares Purchase $117,600 +100,000 +33% $1.18 405,000 15 Dec 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.115 to $1.19, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.195 to $1.20, inclusive. The reporting person undertakes to provide to Aptose Biosciences, Inc., any security holder of Aptose Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.155 to $1.20, inclusive. The reporting person undertakes to provide to Aptose Biosciences, Inc., any security holder of Aptose Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.